

Law Offices of
SENNIGER, POWERS, LEAVITT AND ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
Telephone (314) 231-5400
Facsimile (314) 231-4342

FACSIMILE TRANSMITTAL COVER SHEET

DATE: February 5, 2004 ATTORNEY DOCKET #: 3167/6Z/US (PHA 2005)

PTO FACSIMILE NUMBER: (703) 746-9195

PLEASE DELIVER THIS FACSIMILE TO:

Office of Initial Patent Examination's Filing Receipt Corrections

THIS FACSIMILE IS BEING SENT BY: Kathryn J. Doty, Esq.

NUMBER OF PAGES: 5 INCLUDING COVER SHEET

TIME SENT: 1:58 pm OPERATOR'S NAME M. Susan Clements
(CDT)

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that these papers are being transmitted via facsimile to the Commissioner for Patents on the date shown below.

M. Susan Clements

Typed or printed name of person signing certification

M. Susan Clements
Signature

February 5, 2004
Date

Type of papers transmitted: Request for Corrected Filing Receipt

Applicant's Name: John P. McKearn, et al.

Serial No. (Control No.): 09/857,994 Examiner: _____

Filing Date: October 5, 2001 Art Unit: 1646

Application Title: METHOD OF USING AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA

IF YOU DO NOT RECEIVE ALL PAGES CLEARLY, CALL BACK AS SOON AS POSSIBLE. CONFIRMING NUMBER IS (314) 231-5400.

Senniger, Powers, Leavitt & Roedel

Attorneys at Law

Patents, Trademarks, Copyrights,
Technology Law, Antitrust, LitigationKathryn J. Doty
kdoty@senniger.comOne Metropolitan Square, 16th Floor
Saint Louis, Missouri 63102Telephone: 314-231-5400
Facsimile: 314-231-4342

www.senniger.com

February 5, 2004

Application of John P. McKearn et al.

Art Unit 1617

Serial No. 09/857,994

Filed October 5, 2001

Confirmation No. 4028

For METHOD OF USING INTEGRIN ANTAGONIST AND ONE OR MORE
ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY

Attorney Docket No. PHA 2005 (3167/6Z/US)

Office of Initial Patent Examination's
Customer Service Center
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Sir:

Our firm recently took over the prosecution of the above-referenced patent application. The filing receipt was received (date mailed) October 23, 2001. On February 7, 2002 a Request for Corrected Filing Receipt was filed, however, to date we have not received a Corrected Filing Receipt. The receipt shows the priority information as "This Application is a 371 of PCT/US99/30670 12/22/1999"; whereas the correct priority information is "This Application is a 371 of PCT/US99/30670 12/22/1999 and Claims Benefit of 60/113,786 12/28/98".

* A copy of the Filing Receipt with the changes noted thereon is enclosed. Also
* enclosed is a copy our executed Power of Attorney.

Please send us a corrected filing receipt.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593

KJD/msc
*Enclosure

cc: Patricia G. Keller, Ph.D. (w/o Encl.)



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
WWW.USPTO.GOV

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/857,994	10/05/2001	1646	2700	CU-2561 RJS		115	2

CONFIRMATION NO. 4028

FILING RECEIPT



OC000000006950588

Richard J Streit
Ladas & Parry
Suite 1200
224 South Michigan Avenue
Chicago, IL 60604

Date Mailed: 10/23/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

John P. McKearn, Glencoe, MO;
Gary Gordon, Highland, IL;
James J. Cunningham, Chicago, IL;
Stephen T. Gately, Palatine, IL;
Alane T. Koki, Beaufort, MO;
Jaime L. Masferrer, Ballwin, MO;

Domestic Priority data as claimed by applicant

✓ THIS APPLICATION IS A 371 OF PCT/US99/30670 12/22/1999
AND CLAIMS BENEFIT OF 64/113,786 12/23/98

Foreign Applications

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

Title

Method of using an integrin antagonist and one or more antineoplastic agents as a combination

therapy in the treatment of neoplasia

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).